The specific targeting of signal transduction components implicated in vascular disease may be accomplished more efficiently with genes than with drugs (pages 541–545).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Indolfi, C. et al. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nature Med. 1, 541–545 (1995).
Daum, G., Eisenmann-Tappe, I., Fries, H.-W., Troppmair, J. & Rapp, U.R. The ins and outs of Raf kinases. Trends biochem. Sci. 19, 474–480 (1994).
Feig, L.A. & Cooper, G.M. Inhibition of NIH 3T3 cell proliferation by a mutant Ras protein with preferential affinity for GDP. Molec. Cell. Biol. 8, 3235–3243 (1988).
Bruder, J.T., Heidecker, G. & Rapp, U.R. Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase. Genes Dev. 6, 545–56 (1992).
Al-Alawi, N. et al. Thyrotropin induced mitogenesis is Ras-dependent but appears to bypass the RAf-dependent cytoplasmic kinase cascade. Molec. Cell. Biol. 15, 1162–1168 (1995).
Whitehurst, C.E., Owaki, H., Bruder, J.T., Rapp, U.R. & Geppert, T.D. The MEK kinase activity of the catalytic domain of Raf-1 is regulated independently of Ras binding in T-cells. J. biol. Chem. 270, 5594–5599 (1995).
Bogoyevitch, M.A. et al. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. J. biol. Chem 269, 1110–1119 (1994).
Ross, R. The pathogenesis of atherosclerosis, a perspective for the 1990's. Nature 362, 801–809 (1993).
Powell, J.S. et al. Inhibitors of angiotensin converting enzyme prevent neointimal proliferation after vascular injury. Science 245, 186–188 (1989).
Ottlinger, M.E., Pukac, L.A. & Karnovsky, M.J. Heparin inhibits mitogen-activated protein kinase activation in intact rat vascular smooth muscle cells. J. biol. Chem. 268, 19173–19176 (1993).
Smith, C.D., Wen, D., Mooberry, S.L. & Chang, K.J. Inhibition of phosphatidylinositol 4-phosphate kinase by heparin. A possible mechanism for the antiproliferative effects of heparin. Biochem. J. 281, 803–808 (1992).
Ohno, T. et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265, 781–784 (1994).
James, G.L. et al. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells. Science 260, 1937–1942 (1993).
Kohl, N.E. et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260, 1934–1937 (1993)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ludwig, S., Rapp, U. Cascading towards vascular disorder gene therapy. Nat Med 1, 513–515 (1995). https://doi.org/10.1038/nm0695-513
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0695-513
This article is cited by
-
Gene Therapy for Vascular Disease
Annals of Vascular Surgery (1997)
-
Selective gene therapy for proliferative disorders: Sense and antisense
Nature Medicine (1996)
